Grant ID DP190027
Awarded On February 21, 2019
Title A first-in-class anti-VISTA monoclonal antibody for the treatment of MDSC-mediated suppression of anti-tumor immunity in solid tumors and lymphomas
Program Product Development Research
Award Mechanism Company Relocation
Institution/Organization Hummingbird Bioscience, Incorporated
Principal Investigator/Program Director Piers Ingram
Cancer Sites All Sites
Contracted Amount $13,116,095
Lay Summary

Hummingbird Bioscience, a highly innovative biotech company, with facilities in Singapore and South San Francisco, is applying for a CPRIT Relocation grant to move to Texas. The company has developed a new cancer therapy, HMBD-002-V4, for patients who are resistant to cancer immuno-oncology (IO) drugs.

FDA-approved IO drugs that harness the power of the body’s immune system to fight cancer have made rapid advances in treating patients with cancers who previously had very few options. This includes patients with melanoma, non-small cell lung cancer, kidney and bladder cancer and several others. However, as many as 70% of these patients develop resistance and their cancer progresses, and they ...

Read More